Bristol Myers Squibb (BMY) Gains from Investment Securities (2019 - 2025)

Bristol Myers Squibb (BMY) has reported Gains from Investment Securities for 5 consecutive years, with $15.0 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Gains from Investment Securities changed N/A year-over-year to $15.0 million in Q4 2025; TTM through Jun 2026 was $351.0 million, a 4.46% increase from a year earlier, with the FY2025 full-year figure at $351.0 million, changed N/A from the prior year.
• Gains from Investment Securities was $15.0 million for Q4 2025 at Bristol Myers Squibb, down from $336.0 million in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $336.0 million in Q2 2025 and troughed at -$510.0 million in Q1 2021.
• A 3-year average of -$33.3 million and a median of -$4.5 million in 2022 frame the typical range for Gains from Investment Securities.
• Across the five-year window, Gains from Investment Securities slumped 191.73% in 2021 and jumped 100.2% in 2022, its largest moves.
• Over 3 years, Gains from Investment Securities stood at -$32.0 million in 2021, then surged by 68.75% to -$10.0 million in 2022, then surged by 250.0% to $15.0 million in 2025.
• The last three Gains from Investment Securities figures came in at $15.0 million (Q4 2025), $336.0 million (Q2 2025), and -$10.0 million (Q4 2022), per Business Quant data.